财务状况 - 公司现金、现金等价物和可流通证券截至2024年6月30日为1.627亿美元[15] - 公司预计其资本资源将足以支持其目前的经营计划承诺至2026年[7] 财务业绩 - 第二季度净亏损为2430万美元,每股亏损0.20美元[11] - 第二季度研发费用为1720万美元,较2023年同期减少[9] - 第二季度一般及行政费用为1050万美元,较2023年同期减少[10] - 第二季度合作收入为230万美元,较2023年同期下降[8] 临床试验进展 - XMT-1660剂量递增试验正在进行,计划于2024年下半年公布初步临床数据并启动扩展试验[4] - XMT-2056剂量递增试验正在进行,GSK有独家全球许可选择权[5] 合作进展 - 公司与强生和默克KGaA的合作在推进[6] - 2024年8月,公司从强生合作中获得800万美元的里程碑付款[6]

Dose escalation advancing in Phase 1 clinical trials of both XMT-1660 and XMT-2056 Continue to expect to announce initial XMT-1660 clinical data and initiate expansion in the second half of 2024 Capital resources expected to support current operating plan commitments into 2026 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibo ...

CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the second quarter ended June 30, 2024 on Tuesday, August 13, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Tim ...

CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the second quarter ended June 30, 2024 on Tuesday, August 13, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Tim ...

CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) --  Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the following upcoming investor conferences: TD Cowen 5th Annual Oncology Innovation SummitFormat:        Fireside chatDate/Time:        Wednesday, May 29, 2024, at 9:00 a.m. Ea ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2024 Earnings Conference Call May 9, 2024 8:00 AM ET Company Participants Jason Fredette - Senior Vice President, Investor Relations & Corporate Communications Martin Huber - President & Chief Executive Officer Brian DeSchuytner - Chief Financial Officer & Chief Operating Officer Conference Call Participants Tara Bancroft - TD Cowen Kaveri Pohlman - BTIG Dylan Drakes - Leerink Partners Brian Cheng - JPMorgan Michael Schmidt - Guggenheim Asthika Goonewardene - Trui ...

Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.52 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 11.11%. A quarter ago, it was expected that this company would post a loss of $0.20 per share when it actually produced a loss of $0.16, delivering a surprise of 20%.Over the last four quarters, the company has ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38129 Mersana Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 04-3562403 (State or other jurisdiction of ...

Corporate Presentation May 9, 2024 Legal Disclaimer This presentation contains “forward-looking” statements and information within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions, although not all forward-looking statements conta ...

Exhibit 99.1 Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results - Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024 - Patient recruitment ongoing in Phase 1 clinical trial of XMT-2056; plan to advance dose escalation in 2024 - Continue to expect capital resources will ...